Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145765 | 1.00 | ALDH1A1 (0.62) | ALDH1A1GLATDP1SMN1; SMN2TSHR | |
| SCHEMBL4098812 | 1.00 | ALDH1A1 (0.62) | ALDH1A1GLATDP1SMN1; SMN2TSHR | |
| SCHEMBL19527551 | 0.88 | ALDH1A1 (0.49) | ALDH1A1GLATDP1SMN1; SMN2TSHR | |
| SCHEMBL19527542 | 0.87 | ALDH1A1 (0.46) | ALDH1A1GLASMN1; SMN2KDM4EGAA | |
| SCHEMBL11695226 | 0.85 | ALDH1A1 (0.60) | ALDH1A1GLATDP1SMN1; SMN2TSHR | |
| SCHEMBL22357196 | 0.83 | ALDH1A1 (0.78) | ALDH1A1GLATDP1SMN1; SMN2TSHR | |
| SCHEMBL679937 | 0.83 | ALDH1A1 (0.78) | ALDH1A1GLATDP1SMN1; SMN2TSHR | |
| SCHEMBL1155048 | 0.83 | KDM4E (0.49) | ALDH1A1GLASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL8707600 | 0.82 | ALDH1A1 (0.50) | ALDH1A1GLATDP1SMN1; SMN2TSHR | |
| SCHEMBL19527607 | 0.81 | SMN1; SMN2 (0.46) | ALDH1A1TDP1SMN1; SMN2TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11452712-B2 | Methods and compositions involving (S)-bucindolol | ARCA BIOPHARMA INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20180161309-A1 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | ARCA BIOPHARMA, INC. | 2018-06-14 | — | — | US | disclosed |
| US-9763916-B2 | Methods and compositions involving (S)-bucindolol | ARCA BIOPHARMA, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170000766-A1 | Methods and Compositions Involving (S)-Bucindolol | GENVARA BIOPHARMA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9446023-B2 | Methods and compositions involving (S)-bucindolol | ARCA BIOPHARMA, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9446023-B2 | Methods and compositions involving (S)-bucindolol | ARCA BIOPHARMA, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150190375-A1 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | GENVARA BIOPHARMA, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150190375-A1 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | GENVARA BIOPHARMA, INC. | 2015-07-09 | — | — | US | disclosed |
| US-8946284-B2 | Methods and compositions involving (S)-bucindolol | ARCA BIOPHARMA, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20120108617-A1 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | ARCA BIOPHARMA, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-6818660-B2 | FOR INHIBITING CALCIUM RECEPTOR ACTIVIT; TO STIMULATE SECRETION OF PARATHYROID HORMONE (PTH); FOR BONE FORMATION | NPS PHARMACEUTICALS, INC. | 2004-11-16 | — | — | US | disclosed |
| US-6521667-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | disclosed |
| US-6432656-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020099220-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2002-07-25 | — | — | US | disclosed |
| US-6022894-A | Method of using calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2000-02-08 | — | — | US | disclosed |
| EP-0901459-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997037967-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1997-10-16 | — | — | WO | disclosed |
| EP-0116825-B1 | NEW ARYLOXYPROPANOLAMINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC USE | Pierrel S.p.A. (IT) | 1987-12-16 | — | — | EP | disclosed |
| US-4579861-A | Aryloxypropanolamine derivatives, pharmaceutical compositions and adrenegic thereof | PIERREL S.P.A. (IT) | 1986-04-01 | — | — | US | disclosed |
| EP-0116825-A1 | New aryloxypropanolamine derivatives, process for the preparation thereof, pharmaceutical compositions and therapeutic use | Pierrel S.p.A. (IT) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161309-A1 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | ADRB3, ADRB2, ADRB1 | ALDH1A1 1011/4885GLA 2703/4885TDP1 2218/4885 |
| US-20150190375-A1 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | ADRB3, ADRB2, ADRB1 | ALDH1A1 1011/4885GLA 2703/4885TDP1 2218/4885 |
| US-20120108617-A1 | METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL | ADRB2, ADRB3, ADRB1 | ALDH1A1 631/4885GLA 2597/4885TDP1 2193/4885 |
| US-11452712-B2 | Methods and compositions involving (S)-bucindolol | ADRB3, ADRB2, ADRB1 | ALDH1A1 1011/4885GLA 2703/4885TDP1 2218/4885 |
| US-20020099220-A1 | Calcilytic compounds | CALCR, CASR, CALCRL | ALDH1A1 4285/4885GLA 329/4885TDP1 4636/4885 |
| US-20170000766-A1 | Methods and Compositions Involving (S)-Bucindolol | ADRB3, ADRB2, ADRB1 | ALDH1A1 1011/4885GLA 2703/4885TDP1 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.